This secondary analysis from DEVOTE of patients with T2D at high risk of CV events, treated with basal insulin (degludec or glargine U100) demonstrated no treatment differences with degludec versus glargine U100 in terms of hHF, that prior HF was the strongest predictor of future hHF events, and that there was an association between severe hypoglycemia and subsequent hHF, which was further supported by the similar results from LEADER. Here, INS is linked to type 2 diabetes mellitus.